Navigation Links
Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
Date:12/20/2007

n about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the company will not be able to commence or complete one or more of the seven clinical studies noted above due to any number of factors, including lack of regulatory approval or slower than expected patient enrollment, the risk that the addition of clinical trial sites will not result in increased enrollment, and the risk that Avid may not continue to grow its manufacturing revenue, thereby increasing cashflows, due to the loss of existing clients, or in ability to acquire new clients. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed fr
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... ... Vieillard as Sales & Marketing Director. , With more than 25 years ... responsible for reinforcing Tronics’ business development activities worldwide. He brings to the company ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... the globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online ... contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... in Dallas, TX , ISN has additional offices in Calgary ...
(Date:7/30/2015)... WARRINGTON, Pa. , July 30, 2015 /PRNewswire/ ... announced that it has received the second $1.0M ... Business Innovation Research (SBIR) grant valued at up ... the company,s aerosolized KL4 surfactant as a potential ... lung injury.  Discovery Labs was awarded an initial ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Clinicians now have a new tool to help diagnose symptomatic ... of the most common sexually transmitted infections in the world. ... Dickinson and Company), announced today that it received U.S. Food ... automated molecular tests to detect and differentiate HSV types 1 ...
... Calif., March 28, 2011 BioMarin Pharmaceutical ... announced that Jean-Jacques Bienaime, Chief Executive Officer ... and webcast on Thursday, April 28, at ... 2011 financial results.U.S. / Canada Dial-in Number: ...
... 28, 2011 The Japanese nuclear crisis has caused ... shortages not only in Japan, but as far away ... potassium iodide does not provide generalized radiation protection because ... being bombarded with orders as the radiation hysteria mounts. ...
Cached Biology Technology:BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens 2BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET 2Shortages of Potassium Iodide as Radiation Panic Drives Demand 2
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... fetal heart problems when mothers carry particular antibodies associated ... Yale School of Medicine researchers at the Society for ... , Congenital heart block (CHB) is present at or ... the upper to the lower chambers. CHB carries a ...
... causes an animal's immune system to produce antibodies that ... reproductive process. The antibodies can act against sperm, eggs ... production of sperm and ova. , Proponents ... years ago, regard it as more humane than the ...
... an unusual high-energy state produced in single nucleotides -- the ... ultraviolet (UV) light. , This is the first time scientists ... so called because it cannot be detected by fluorescence techniques ... UV light. , The study suggests that DNA employs ...
Cached Biology News:Manipulating nature: Scientists query wildlife birth-control method 2New study sheds light on 'dark states' in DNA 2
... are designed for quick and easy protein ... feature two 0.25mm holes laser cut at ... wells remain liquid-tight during incubation of the ... the protein diffuses from the gel into ...
... western blots ,• Optically clear plastic construction ... western blots. The reduced size (60 x ... tray requires less dye and antibodies resulting ... user. Pour spouts in each corner facilitate ...
... perform many sophisticated DNA analysis and protein analysis ... just another sequence analysis product. Imagine having the ... to be performed each time you have a ... which specify exactly how your output will look ...
These stopping screens are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 screens....
Biology Products: